Onkos Surgical Receives $35 Million Venture Loan from Horizon Technology

Horizon Technology Finance Corporation, an affiliate of Monroe Capital and a leading specialty finance company, has provided a $35 million venture loan facility to Onkos Surgical (Onkos).

$30 million has been initially funded, and the rest of the funding will go towards the manufacturing and commercialization of NanoCept, a groundbreaking, antibacterial coating technology that is used on FDA-granted orthopaedic implants to reduce bacterial contamination at the time of implantation.

Onkos Surgical is an innovator in the musculoskeletal space, developing technologies that address the clinical challenges associated with complex orthopaedic procedures. The company’s product portfolio provides solutions for adult and pediatric patients who have bone loss from tumors, trauma, or revision of failed orthopaedic implants.

“We are committed to transforming the standard of care across complex orthopaedic procedures, with the goals of providing benefit to patients, clinicians, and health systems while creating value for our investors as we expand our footprint in a $3 billion market,” said Patrick Treacy, Onkos Surgical CEO, and Co-founder. “Horizon’s support will further fuel our growth engine by accelerating the commercialization of NanoCept, a transformative and first-of-its-kind orthopaedic technology that has substantial potential to meaningfully improve patient outcomes.”

In April 2024, NanoCept was granted the first-ever FDA De Novo authorization for an antibacterial coating technology used on orthopaedic implants, demonstrating Onkos’s innovation capabilities.

 NanoCept has demonstrated excellent safety and biocompatibility, with broad-spectrum efficacy (up to 99.999% kill rate in standardized in-vitro testing of bacteria commonly found in the operating room environment).

“Onkos Surgical is disrupting the orthopaedic marketplace with a suite of differentiated products, including NanoCept,” said Gerald A. Michaud, President of Horizon. “We are pleased to support the growth of Onkos as it continues to innovate novel solutions that address diverse unmet needs in a growing and important market segment.”